In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials
Fierce Pharma
FEBRUARY 29, 2024
But a new funding pact between Carlyle’s Abingworth and Gilead Sciences is somewhat unconventional. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.
Let's personalize your content